No association between decreases in serum immunoglobulin (Ig) levels below lower limit of normal (LLN) and serious infections (SI) with long-term ublituximab (UBL) treatment in patients with relapsing Multiple Sclerosis (RMS)

Drug Category: Array
Conference Category: Array
Lead Author: Steinman L, et al.
Published Date: 07/04/2025
Download Link: /wp-content/uploads/2025/09/AAN-2025-5-year-Ig-LLN-and-SI-FINAL.pdf
Download Text:
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top